Drug page
SGLT2 inhibitors
SGLT2 inhibitors are oral glucose-lowering drugs that have shown heart and kidney benefits in outcome trials. This page gathers every report on the class.
Reports
- twiist automated insulin delivery in type 2 diabetes: 13-week single-arm trialOther study · 10 October 2026
- ADA and EASD 2026 consensus: earlier SGLT2 inhibitor and/or GLP-1-based therapy in type 2 diabetesGuideline · 10 October 2026
- Oral safiglipron versus dapagliflozin in type 2 diabetes: phase 3 trial in ChinaRandomised trial · 10 October 2026
Page updated 10 October 2026.
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.